The shortage-based legal exemption that underpinned widespread compounded semaglutide availability is no longer active for either 503A pharmacies or 503B outsourcing facilities Compounded GLP-1 programs operating today must navigate a legal framework that includes restrictions on compounding drugs that are commercially available drugs - meaning the compounding pharmacy's specific formulation, documentation, and prescriber individualization process matters for legal compliance The FDA still permits compounding under 503A for individual patient-specific prescriptions that involve a prescriber-documented "significant difference" from the commercially available product - but that requires specific clinical justification, not just a standard intake form Availability of specific compounded GLP-1 formulations may be affected by FDA enforcement actions, pharmacy-specific compliance status, and ongoing regulatory developments in this space None of this means compounded GLP-1 programs are operating illegally
Lilly's Orforglipron, Retatrutide Named as Defining GLP-1 Drugs of the Next Decade
Your provider can adjust your plan as needed and address any concerns that arise during treatment
2026 Formulary Links: SG CA ACA HMO: 2026 Aetna Health Exchange Plan CA SG HMO SG CA ACA OAMC/PPO: 2026 Aetna Health Exchange Plan - CA SG PPO (California) As of January 1, 2025, all GLP-1 drugs have been reclassified from Tier 3 non-formulary to Tier 4 specialty drugs
129 Paroxetine has also been shown to inhibit the inflammatory response in UC by blocking the interaction between G protein-coupled receptor kinase 2 (GRK2) and prostaglandin E2 receptor 4 (EP4), thereby reducing cyclic adenosine monophosphate (cAMP) levels and regulating M2 macrophage polarization
.jpg)
